Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

HCT Recipients Acquire Rare, Potentially Harmful Clonal Mutations Harbored by Younger Donors

Some patients with acute myeloid leukemia (AML) who received a hematopoietic cell transplantation (HCT) from young donors acquired rare, yet potentially harmful, clonal mutations...

Adding Isatuximab to Dexamethasone-Pomalidomide Combination Improves Progression-Free Survival in Pretreated Myeloma

Treatment with the investigational anti-CD38 monoclonal antibody isatuximab plus the combination of pomalidomide and low-dose dexamethasone (Pd) led to a median progression-free survival (PFS)...

Outcomes With Idelalisib Differ in the Clinical Trial Versus Real-World Setting

According to a real-world analysis published in JAMA Oncology, treatment outcomes with idelalisib differed between patients with follicular lymphoma (FL) and chronic lymphocytic leukemia...

Study Finds No Benefit With Post-Induction Treatment Intensification in Children With ALL

According to results from the Children’s Oncology Group AALL0331 trial, pediatric patients with standard-risk B-cell acute lymphocytic leukemia (ALL) had a high rate of...

How Common Is Serotonin Release Assay-Negative Heparin-Induced Thrombocytopenia?

Heparin-induced thrombocytopenia (HIT), a prothrombotic drug reaction caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies, is commonly diagnosed with the platelet serotonin-release assay (SRA)...

A 42-Item Frailty Index Improves Survival Prediction in Myelodysplastic Syndromes

In a recent Leukemia paper, researchers reported on a new 42-variable frailty index (FI) for patients with myelodysplastic syndromes (MDS), which appears to improve...

Evaluating Efgartigimod in Patients With Primary Immune Thrombocytopenia

Treatment with the neonatal Fc receptor antagonist efgartigimod led to clinically relevant increases in platelet counts in patients with primary immune thrombocytopenia (ITP), according...

Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive...

For patients with aggressive B-cell non-Hodgkin lymphoma (NHL) and a favorable prognosis, treatment with four cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and...

Asciminib Shows Durable Clinical Activity in Heavily Pretreated CML

In a phase I, dose-escalation study, treatment with asciminib was active and associated with durable responses in more than half of patients with chronic...

ALCYONE Update: Adding Daratumumab to VMP Improves Survival in Transplant-Ineligible Myeloma

In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP)...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title